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2352-3964/© 2015 The Authors. Published by Elsevier B.VKidney cancer is the seventh most common site for tumors, with For the ﬁrst time, this study identiﬁes a multimarker prognostic
350,000 new cases diagnosed in 2013 worldwide and is associated
with more than 140,000 deaths per year. In the USA, 61,560 new cases
are estimated in 2015 (Ferlay et al., 2013; Capitanio and Montorsi,
2015). Despite several advances, about 30% of patients have ametastatic
disease at diagnosis (Gupta et al., 2008) and another 30% of patientswill
have a relapse after nephrectomy and will become metastatic during
follow-up (Athar and Gentile, 2008). Risk group stratiﬁcation is useful
to optimize treatment decisions and maximize patient survival.
In this issue of EBioMedicine (Kim et al., 2015), Hyung Lae Kim and
colleagues have described an 8-gene model of overall survival (OS)
using primary untreated renal cell carcinoma (RCC) formalin-ﬁxed,
parafﬁn-embedded specimens collected for Cancer and Leukemia
Group B (CALGB) 90206 trial, which was a randomized phase III, open
label study comparing bevacizumab plus interferon alpha (IFN) versus
IFN alone (Rini et al., 2010). The CALGB 90206 trial has demonstrated
a beneﬁt, in terms of progression-free survival (PFS), in favor of the
combination therapy (median PFS 8.5 vs 5.2 months, p b 0.0001), but
no OS beneﬁt (median 17.4 and 18.3 months in monotherapy and
combination therapy arm respectively, p = .097). Patients included in
the study had a metastatic or unresectable clear cell renal cell carcino-
ma; 353 tumor samples have been analyzed, but 29 of them have failed
quality control. The ﬁnal analysis of clinical outcome was based on 324
patients, which have been stratiﬁed according to the Memorial Sloan–
Kettering Cancer Center (MSKCC) risk factors, the only clinical variable
included in the ﬁnal multivariable model.
By using a RT-qPCR, the authors measured 424 candidate genes,
identifying 21 prognostic genes with a q-value b0.05 that were selected
for themultivariate analysis that has lead to the identiﬁcation of 8 genes
predictingOS. The ﬁnal prognosticmodel described includes polybromo
1 (PBRM1) related genes (which is the second most important gene in
RCC with Von Hippel–Lindau related genes—VHL), whose functions
are involved with cancer progression such as: CEP55, PCNA, CDK1
(involved in proliferation), TRAF2 (involved in apoptosis), CRYL1,
HSD17B10 (involved in metabolism), and HGF (involved in invasion)
(http://www.ncbi.nlm.nih.gov/gene, n.d.; Tun et al., 2010). This
experience has shown that decreasing levels of CRYL1, PCNA and
CDK1 are associated with a worse OS, while the expression of TRAF2,
USP6NL, CEP55, HGF and HSD17B10 has an inverse association.om.2015.09.012.
it (G. Procopio).
. This is an open access article undersignature in amulticenter, phase III trial onmRCC. A ﬁrst advantage of ex-
trapolating data from a large multicenter study, as the authors state, is
that it is less vulnerable to bias introduced by the single institution proce-
dures about tissue handling and storage. Another strong point of this
study is that, while other biomarker studies also included patients with
localized and non-metastatic RCC, Kim and colleagues' study includes
only advanced disease, permitting a more practice clinical application in
a group of patients in which RCC is associated with a bad prognosis. The
methods used to identify genes, based on real-timePCR, are routinely per-
formed bymany hospitals and laboratories and they are highly reproduc-
ible and usually inexpensive in clinical practice, making the study very
interesting in the identiﬁcation of predicting and prognostic factors in
RCC. Although Kim and colleagues' study is very extensive and well de-
scribed, the main limitation is the lack of an external validation cohort.
The study is a good example of molecular research; it highlights
the need for identiﬁcation of prognostic factors and predictive ones
and provides new molecular targets. The originality of this paper is
the identiﬁcation of a molecular multimarker prognostic signature in
RCC, which supports the well known clinical prognostic factors.
These ﬁndings raise some points for further investigation. First, the
identiﬁcation of a model of genes predictive of OS in RCC, together with
the best known MSKCC risk factor, could allow physicians to stratify and
select patients for the best treatment strategies. These ﬁndings highlight
the need for identifying new molecular predictive factors that can en-
hance clinical ones (which are largely available and solidly used in clinical
practice). Second, itwould be interesting to establish if the expression of a
particular gene among those identiﬁed is a predictive factor of response or
resistance to speciﬁc treatments. This will certainly guide treatment deci-
sions. Third, methodology should be simple and standardized in order to
beduplicated in a real-worldunselectedpopulation. Finally, appropriately
sized and rigorously evaluated prospective studies or prospectively col-
lected external datasets would be useful to put this method and these
ﬁndings into clinical practice.Conﬂicts of Interest
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